Degastril is a medication used for the relief of symptoms associated with excessive stomach acid. The medicine is employed in clinical scenarios to help manage discomfort from conditions such as gastroesophageal reflux disease (GERD), mild esophagitis, heartburn, and dyspepsia (indigestion). The goal of treatment is to support a reduction in the intensity and frequency of these distressing symptoms, thereby helping to improve daily comfort.

Its uses include the management of sour stomach and acid indigestion. These indications fall within recognized therapeutic domains which outline the use for this category of medicine.

“The proper use of this type of medication can significantly contribute to symptomatic well-being.”

---

Quick Fact: Relief for Heartburn and Acid Indigestion

---

Who Can and Cannot Use Degastril?

Degastril (Sucralfate) eligibility is strictly defined by regulatory documents, focusing on absolute prohibitions and population restrictions.

Contraindications: Use is contraindicated for patients with a known hypersensitivity to the active ingredient or any excipient. The product is also absolutely prohibited for intravenous (IV) administration.

Age and Special Populations: The medicine is established for adults. For children under 14 years of age, safety and efficacy have not been established, leading to a regulatory recommendation against its use. Older adults require cautious dose selection, particularly related to monitoring renal function.

Condition-Specific Restrictions: Patients with chronic renal failure or on dialysis must use the medicine with extreme caution and often for short-term treatment only. This restriction is due to the risk of systemic aluminum accumulation. Caution is also required for individuals with delayed gastric emptying or other GI motility disorders due to the risk of physical obstruction (bezoar formation).

Pregnancy and Lactation: Use during pregnancy is advised only if clearly needed (classified as FDA Pregnancy Category B). Caution should be exercised during breastfeeding, as it is unknown whether the drug is excreted in human milk.

Interactions with other medicines and products

Degastril's official interaction profile is characterized by its nonsystemic mechanism, primarily affecting the absorption of co-administered oral medicines within the gastrointestinal tract. This interaction pattern leads to a reduced extent of absorption (bioavailability) for several drugs, necessitating specific restrictions as defined by regulatory authorities.

Official Interaction Statements

Interaction Type	Interacting Substances & Constraint
Reduced Exposure	Digoxin, Phenytoin, Warfarin, Fluoroquinolone antibiotics, L-thyroxine, Cimetidine, and Theophylline are among the agents that may have reduced systemic exposure.
Administration Timing	Co-administered oral medications must be administered 2 hours prior to Degastril when stable systemic drug levels are clinically critical. Antacids require separation of at least 30 minutes before or after Degastril.
Additive Risk	Concomitant use with aluminum-containing products or substances containing Citrate/Citric Acid can significantly increase the total systemic body burden of aluminum.

Population-Specific Interaction Notes

The risk of aluminum accumulation and toxicity is a specific concern for patients with chronic renal failure or those on dialysis, due to impaired excretion of absorbed aluminum. Additionally, co-administration with enteral (tube) feedings may lead to tube obstruction or reduced efficacy, an interaction constraint noted in official labeling.

How Degastril Works

The core action of Degastril (Sucralfate) is defined by its localized cytoprotective mechanism that relies on both physical barrier formation and the biochemical enhancement of endogenous defenses.

---

Acid-Activated Formation of a Physical Barrier

This domain explains how the molecule transforms in the low-pH environment of the stomach, enabling it to electrostatically bind to the exposed proteins in the base of an ulcer or erosion. This binding creates a viscous, dense, protective layer that physically isolates the damaged tissue, resulting in the creation of a physical diffusion barrier.

---

Chemical Shielding and Enzymatic Neutralization

This section details how the protective layer formed by the drug's active ingredient actively adsorbs and inactivates destructive digestive agents like pepsin and bile salts. This mechanism limits ongoing proteolytic and chemical damage at the injury site. The absence of enzymatic damage permits the engagement of epithelial repair mechanisms.

---

Local Enhancement of Mucosal Defense Factors

Beyond physical shielding, this domain involves the localized modulation of cellular signaling that leads to the enhancement of the gastric mucosal defense system. The drug indirectly stimulates the synthesis of prostaglandin E2, leading to increased local blood flow and the secretion of protective mucus and bicarbonate left( HCO3^- ight), thereby increasing the tissue's resistance to H^+ ion penetration.

Official Administration Guidelines for Degastril

Degastril (degarelix) is provided as a powder that must be reconstituted immediately before use with Sterile Water for Injection, USP. The medication must be administered by a healthcare professional.

---

Dosing and Schedule

Dose Type	Amount and Frequency	Administration
Starting Dose	240 mg (given once)	Administered as two separate 120 mg subcutaneous injections.
Maintenance Dose	80 mg (given every 28 days)	Administered as one single subcutaneous injection.

The first maintenance dose should be given 28 days after the starting dose. No dose adjustment is typically recommended for patients with mild to moderate kidney or liver impairment, though caution is advised in severe cases.

---

Administration Procedure

Route and Site: Degastril is for subcutaneous use only and must not be administered intravenously (IV). The injection must be given into the abdominal region.

Special Conditions:

• Site Rotation: The injection site should vary periodically during treatment.
• Pressure Avoidance: Injections should only be given in areas of the abdomen that will not be exposed to pressure, such as near a waistband or belt.
• Preparation: The reconstituted drug must be administered within one hour after mixing with the sterile water. Vials should be swirled gently and not shaken.
• Technique Check: The procedure requires a gentle pullback of the plunger to check for blood aspiration; if blood is seen, the injection must be aborted and a new dose prepared.

Missed Dose: If a maintenance dose is missed, it should be administered as soon as possible, and the 28-day cycle should resume from that date.

Research evidence / Overview of studies for Degastril

Degastril (sucralfate) was evaluated in research contexts involving certain conditions of the upper gastrointestinal tract. The primary body of evidence consists of short-term randomized controlled trials (RCTs), meta-analyses, and observational studies, which research monitored, assessing changes in healing status and symptoms in various patient groups.

---

Evidence for Use in Active Duodenal Ulcers

The initial clinical evaluation of Degastril primarily involved short-term Randomized Controlled Trials (RCTs). These studies examined research contexts involving active duodenal ulcers, which are a type of damage to the lining of the small intestine. Studies monitored adult participants diagnosed with these ulcers over periods of four to eight weeks. The main outcomes related to physical discomfort measured included the rate at which the ulcers healed and patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies regarding the change in re-epithelialization status of the ulcers. Long-term effects are not fully established from these short-term healing trials.

---

Evidence for Preventing Ulcer Recurrence (Maintenance)

Following initial healing, Degastril was evaluated in trials that monitored the risk of recurrence of duodenal ulcers in adult patients. The primary outcomes reflecting disease relapse that researchers monitored were related to the frequency of ulcer recurrence. Research highlights changes measured during the study period related to relapse frequency. However, follow-up durations were limited, often extending up to one year. There is limited information regarding recurrence prevention extending beyond twelve months, especially in patients who have received modern bacterial eradication therapy.

---

Evidence in Preventing Stress-Related GI Bleeding

Degastril was studied for use in highly specialized, critically ill adult populations. The evidence here is supported by Systematic Reviews and Network Meta-analyses that summarize outcomes from trials comparing Degastril to other prophylactic agents. The outcomes monitored included the rate of occurrence of clinically significant gastrointestinal bleeding, as well as the frequency of secondary complications. The compiled evidence shows inconsistent results when comparing the rate of bleeding to that observed with other prophylactic agents. Evidence quality varies across studies, and data may not fully reflect its performance in modern critical care settings.

---

Long-Term Evidence and Durability of Effect

The follow-up durations were limited across the core research base for Degastril. While maintenance studies provided up to a year of observation, there is a consistent gap in research exploring outcomes beyond that period. Therefore, long-term effects are not fully established, and there is limited information regarding the extended durability of any observed response after treatment is stopped. The current evidence primarily describes short-term changes and intermediate-term recurrence patterns. Data comparing outcomes in modern settings for many secondary uses remains limited.

Key Studies & References

1. Sucralfate (StatPearls - NCBI Bookshelf)
2. Sucralfate Official Labeling and Monograph (National Library of Medicine - DailyMed)

Common questions about Degastril (FAQ)

Q: What are the most common side effects people notice when starting Degastril?

According to official regulatory documents, the most frequently reported adverse effect in clinical trials is constipation, which was noted in approximately 2% of patients. A full description of known adverse effects is available in the section on 'Possible side effects and safety information.'

Q: How long does it typically take for Degastril to start working?

Studies on the medicine's mechanism indicate that the initial action of the medicine can be observed within 1 to 2 hours after a dose is taken. However, for the ultimate goal of healing ulcers, the prescribed course of therapy typically lasts for 4 to 8 weeks.

Q: How quickly does Degastril leave the body after I stop taking it?

Official information indicates that the active ingredient in Degastril is minimally absorbed (less than 5%) from the digestive tract. Because it acts locally and is absorbed so little, most of the medicine that is not used locally is passed out of the body unchanged in stool.

Q: Is Degastril safe to use long-term?

Regulatory documents indicate the medicine is approved for short-term treatment (up to 8 weeks) and also for maintenance therapy. However, caution is advised for long-term use, especially in patients with impaired kidney function, due to the possibility of aluminum building up in the body.

Q: Are there any warnings about driving or operating machinery while on Degastril?

Official reports on adverse reactions include potential effects on the nervous system, such as dizziness and sleepiness (drowsiness). The presence of these effects may be associated with warnings in patient information regarding caution when driving or operating machinery.

Q: Why do some people experience mild headaches with Degastril?

Headache is listed as an adverse reaction in the official product information, although it was reported in less than 0.5% of patients in clinical trials. It is a known, though uncommon, effect associated with the use of the medicine.

Q: Is Degastril similar to a proton pump inhibitor (PPI)?

Degastril is not in the same pharmacological class as a PPI. PPIs work systemically by chemically reducing acid production in the stomach. Degastril has a local action, working instead by forming a physical protective barrier over damaged tissue.

Q: Is Degastril used to prevent a condition, or only to treat active symptoms?

Official indications confirm the medicine is used for both purposes. It is indicated for the short-term treatment of existing duodenal ulcers, and it is also indicated for maintenance therapy to help prevent those ulcers from returning after they have healed.

Q: Does Degastril need to be taken at the exact same time every day?

Official patient information advises taking the medicine around the same times every day. This guidance is provided to help maintain a consistent treatment schedule.

Q: Does Degastril affect laboratory test results?

Official testing guidelines state that the medicine does not interfere with standard H. pylori stool antigen tests. However, it may cause false-positive results with certain laboratory methods used to check for occult blood in the stool.

Q: Are there any specific dietary restrictions associated with taking Degastril?

There are no specific food restrictions mentioned in the official labeling. The main regulatory guidance is related to timing: the medicine must be taken on an empty stomach, typically 1 hour before or 2 hours after meals, as its action is dependent on specific timing relative to food intake.

Q: What is the difference between Degastril and standard antacids?

Antacids work by neutralizing acid, while Degastril creates a physical protective barrier over damaged tissue. Official administration instructions specify that antacids must be taken at least 30 minutes before or after Degastril to avoid interference with its effect.

Q: Can I drink coffee or tea while taking Degastril?

The official label does not list coffee or tea as specific interactions. However, since the medicine's action is highly localized, the consumption of any food or beverage (other than water) is generally separated from the dosing time by 1 hour before or 2 hours after a dose.

Q: Can I stop taking Degastril suddenly?

The medicine is generally prescribed for a complete course of 4 to 8 weeks in studies that evaluate ulcer healing. Patients are advised to complete the full treatment course as prescribed, even if symptoms begin to improve early.

Q: Is Degastril available without a prescription?

Degastril is officially classified as a prescription-only medication in regulated markets.

Q: Does Degastril affect sleep?

Adverse reactions reported in clinical trials include insomnia (difficulty sleeping) and sleepiness (drowsiness). Both of these effects were reported in less than 0.5% of patients.

Q: Is it possible to take Degastril if I am also taking an over-the-counter pain reliever?

The medicine may reduce the absorption (bioavailability) of several orally administered medications, including some pain relievers. To help prevent reduced drug exposure, official labeling advises a separation of at least 2 hours between Degastril and co-administered oral medications.

Q: Can Degastril cause dizziness?

Dizziness is listed as a potential adverse reaction in the official product information. It was reported in less than 0.5% of patients in clinical trials.

Q: Is it normal to have a dry mouth while using Degastril?

Dry mouth is listed as an uncommon adverse reaction in the official documents, reported in 0.1% to 1% of patients in clinical trials.

Q: Does Degastril cause issues with blood sugar levels?

Official warnings note that cases of hyperglycemia (high blood sugar) have been reported in diabetic patients using the oral suspension form. Close monitoring of blood sugar levels has been advised for diabetic patients using this medicine.

How to Store and Dispose of Degastril

Storage and disposal requirements for Degastril (Sucralfate) are defined by official regulatory labeling to maintain the product's integrity and ensure safety.

---

Storage Requirements

Requirement	Official Regulatory Statement
Temperature	Store at Controlled Room Temperature, mathbf20 C to mathbf25 C (mathbf68 F to mathbf77 F).
Freezing Protection	The oral suspension must be protected from freezing.
Container Rule	The oral suspension container must be kept tightly closed.
Child Safety	Keep out of the reach and sight of children.

---

Disposal

Official instructions require that unused or expired product must be disposed of in accordance with local requirements. This mandate directs users to follow proper pharmaceutical waste guidelines in their area.